Targeting HDL-cholesterol to reduce residual cardiovascular risk

Curr Opin Lipidol. 2012 Apr;23(2):172-4. doi: 10.1097/MOL.0b013e32835135bd.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Atorvastatin
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, HDL / blood*
  • Fluorobenzenes / therapeutic use
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / drug therapy*
  • Pravastatin / therapeutic use
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Risk Factors
  • Rosuvastatin Calcium
  • Sulfonamides / therapeutic use

Substances

  • Cholesterol, HDL
  • Fluorobenzenes
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • Rosuvastatin Calcium
  • Atorvastatin
  • Pravastatin